Clinical Heamatology Research and Publications
Details of Research
- Funded Project
Duration: January 2024 to December 2024 (Excluding Clinical Trials)
|
Sr. No. |
Title of Project |
Proposal No. (IEC No.) |
Name of Principle Investigator |
Amount of Grant Received |
Name of Funding Agency |
Collaboration with other institute (if any) |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
ICMR ISCALL: ICiCLE Implementation study | IEC/PHARMAC/2023/710 | Dr. Vishvdeep Khushoo | Rs. 3,311,378.2 | ICMR | Hub Spoke Model Study | Ongoing | NO |
|
2 |
A multicenter, open -label, randomized, phase III clinical trail to evaluate efficacy and safety, PF-114 versue imatinib at 600 or 800 mg daily in adult patients with Philadelphia chromosome positive (ph+) CML IN CP resistance to imatinib at daily doses of 400 or 600mg. | Dr. Vishvdeep Khushoo | cliantha | Ongoing | NO | |||
|
3 |
A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (ASHA 1) | ECCT/PHARMAC/2023/355 | Dr. Vishvdeep Khushoo | Rs. 4,20,125 | Cliantha | NA | Ongoing | NO |
-
Clinical Trials
|
Sr. No. |
Title of Project |
Clinical Trial No. |
Name of Principle Investigator |
Amount Received |
Sponsors |
Status of Project (Ongoing/ Completed) |
Publication (YES/NO) |
|
1 |
ICMR ISCALL: ICiCLE Implementation study |
IEC/PHARMAC/2023/710 |
Dr. Vishvdeep Khushoo |
Rs. 3,311,378.2 |
ICMR |
Ongoing |
No |
|
2 |
A multicenter, open -label, randomized, phase III clinical trial to evaluate efficacy and safety, PF-114 versue imatinib at 600 or 800 mg daily in adult patients with Philadelphia chromosome positive (ph+) CML IN CP resistance to imatinib at daily doses of 400 or 600mg. | Dr. Vishvdeep Khushoo | Cliantha |
Ongoing |
No |
||
|
3 |
Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (ASHA 1) | ECCT/PHARMAC/2023/355 | Dr. Vishvdeep Khushoo | Rs. 4,20,125 | Cliantha |
Ongoing |
No |
-
Undergraduates/Postgraduates/PhD Research
1.Evaluation of effect of hydroxyurea treatment on inflammatory and oxidative stress markers among adults with Sickle cell disease
2.Comparision of LILRA3 levels between patients with thrombotic and non-thrombotic APLA syndrome
3.Study of association between lymphocyte subset analysis in bone marrow at diagnosis and risk category and post treatment response assessment in cases of acute leukemia- a prospective observational study
Publications
DR. SANTOSH RATHOD
1.Khan AA, Rathod SG.Hereditary Dehydrated Stomatocytosis due to PIEZO1 Mutation and Potential Therapeutic Target for Sickle Cell AnaemiaJ Clin of Diagn Res.2025; 19(7):GL01-GL02.
2.Rathod, S. G., Kabir, S., Geelani, S. A., Khan, A. A., Roshan, R., & Bhat, J. R. (2025). Congenital Methemoglobinemia: A Cause of Polycythemia. Indian journal of pediatrics, 92(4), 431
3.Rathod SG, Sakthivel V, Vane A, Kabir S, Khushoo VK. Fatal intracranial bleedings in a viper bite. Chin J Traumatol. Published online July 21, 2025.
4.Sabharwal D, Rathod SG. Local envenomation by green pit viper complicated with airway obstruction. Turk J Emerg Med. 2025 Jul 1;25(3):250. doi: 10.4103/tjem.tjem_110_25. PMID: 40746571; PMCID: PMC12309814.
5.Rathod SG, Kabir S, Kandi K. Floor Bed, Acute Abdomen, and Descending Paralysis: A Clinical Presentation of Krait Bite. J Pharm Bioallied Sci. 2025 Sep;17(Suppl 3):S2846. doi: 10.4103/jpbs.jpbs_1020_25. Epub 2025 Sep 20. PMID: 41164699; PMCID: PMC12563983.
DR. VISHVDEEP KHUSHOO
1. Mehta, D. M.P., Khushoo, V. Is Old (Fludrabine/Busulfan/CyclophosphamideltAntiThymocyte Conditioning StillGold for Allogeneic Transplants in Transfusion Dependent Beta-Thalassemia of AllRisk Categories in 21st Century? Indian J Hematol Blood Transfus 39, 615-623 (2023). https:/doi.org/10.1007s12288-023 01646-1 Globulin)
2. Mehta, Pallavi & Khushoo, Vishvdeep. (2023). Haploidentical Stem Cell Transplantation for Hematological Disorders: Real-World Experience from India. South Asian Journal of Cancer. 10.1055/s-0043-1771274.
Mirgh S, Sharma A, Shaikh MRMA, Kadian K, Agrawal N, Khushoo V, Mehta P, Ahmed R, Bhurani D. Hypomethylating agents+venetoclax induction therapy in acute myeloid leukemia unfit for intensive chemotherapy - novel avenues for lesser venetoclax duration and patients with baseline infections from a developing country. Am JBlood Res. 2021 Jun 15;11(3):290-302. PMID: 34322294: PMCID: PMC8303019.
3. Jadhav, S., Naik, M., Ojha, N.,Sahoo, T., Panchal, A., et,al. (2024). Application of Optical Genome Mapping to the Risk Stratification and Treatment Optimization of Hematologic Diseases. AdvHema Onco Res, 7(2), 01-10.
4. Yadav, Neha'; Mirgh, Sumeet P.123, Aggarwal, Mukul'; Agrawal,Narendra';Mehta, Pallavi'; Khushoo, Vishvdeep'; Kapoor, Jyotsna';Bhatia,Niharika'; Agrawal, Pragya'; Ahmed, Rayaz'; Bhurani, Dinesh. Secondstemcell transplantation for treatment of relapsed/refractory multiple myeloma after first autologous stem celltransplant: A15-year retrospective institutional analysis. Indian Journal of Cancer 60(3): p 316-324, Jul-Sep 2023.DOl: 10.4103/jc.IJC_272_21
5. Sab, Pinjari Chinigi; Khushoo, Vishvdeep2; Erythrocytapheresis in a sickle cell disease patient with a thalamic space-occupying lesion. Asian Journal of Transfusion Science ():10.4103/ajts.ajts_58_24, July 22, 2025. | DOI: 10.4103/ajts.ajts_58_24
6. Khushoo V, Gade N, Pandoraea pnomenusa Bacteremia in an Acute Myeloid Leukaemia Patient: A Rare and Emerging Pathogen. Clin Case Rep Open Access. 2025;8(2):335.
7. Singh S, Choudhary S, Srivastava A, Prakashey AR, Khushoo V. Hereditary haemorrhagic telangiectasia in skin of colour: a dermoscopic, histopathological and radiological approach. BMJ Case Rep. 2025 May 28;18(5):e265940. doi: 10.1136/bcr-2025-265940. PMID: 40441746.